methyl-CpG binding domain protein 1Genealiases: CXXC3 · PCM1 · RFT
Q-omics provides the consensus-scored MBD1 profile across patient tissues and cancer cell-line models. MBD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MBD1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, MBD1 RNA expression shows 20,492 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MBD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBD1 survival associations across molecular data types. MBD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBD1 RNA expression–survival associations across cancer types. High MBD1 expression shows unfavorable associations in ACC, LIHC, MESO, SKCM and BLCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MBD1 RNA expression.
This table summarizes MBD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MBD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBD1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, KIRC, CHOL and LUSC. The HNSC box plot shows higher MBD1 RNA expression in tumor versus normal tissue (log2 FC = +0.675, t-test p < 0.001).
This table shows molecular features associated with MBD1 in patient tissues and cancer cell lines. In patient samples, MBD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MBD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
